Clinical Trial Update: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC [Phase 2]

View source ↗

Summary

Phase 2 trial of bemcentinib plus pembrolizumab in triple-negative and inflammatory breast cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bemcentinib (bemcentinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: BerGenBio ASA | Conditions: Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV | Phase 2 | Status: TERMINATED | Results posted: 2021-11-09